title: Anabolic therapies for osteoporosis.
abstract: As the first FDA-approved anabolic agent for osteoporosis, teriparatide has proven effective for people at highest risk of fracture, despite limitations of expense, route of delivery, and length of treatment. Available data show that combination therapy with teriparatide and antiresorptive agents does not offer a therapeutic advantage. However, treatment with an antiresorptive agent after teriparatide discontinuation is essential to prevent the ensuing bone loss. Although pretreatment with bisphosphonates may somewhat attenuate the anabolic effect of teriparatide, significant gains in bone mineral density are still achieved and prior bisphosphonate use should not dissuade clinicians from using teriparatide in select patients.
authors.affiliation: Endocrine Unit, Massachusetts General Hospital, 50 Blossom Street, Thier 1051, Boston, MA 02114, USA.
authors.forename: Alexander V
authors.initials: AV
authors.lastname: Uihlein
authors.forename: Benjamin Z
authors.initials: BZ
authors.lastname: Leder
mesh_terms: D019386:Alendronate / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D045930:Anabolic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001842:Bone and Bones / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D016503:Drug Delivery Systems; D016903:Drug Monitoring; D004359:Drug Therapy, Combination / Q000009:adverse effects; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D058866:Osteoporotic Fractures / Q000517:prevention & control; D012516:Osteosarcoma / Q000139:chemically induced / Q000150:complications / Q000517:prevention & control; D019379:Teriparatide / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D045930:Anabolic Agents; D050071:Bone Density Conservation Agents; D015507:Drugs, Investigational; D005938:Glucocorticoids; D019379:Teriparatide; D019386:Alendronate